Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals (XFOR) announced the acceptance of two abstracts for poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) in Milan. The presentations will showcase results from their completed Phase 2 trial of mavorixafor in treating primary chronic neutropenic (CN) disorders.
The six-month, open-label clinical trial enrolled 23 participants with idiopathic, congenital, or cyclic chronic neutropenia. Key findings include meaningful and durable increases in functional neutrophils with once-daily oral mavorixafor, and most physicians and participants opted to reduce G-CSF dosing when using mavorixafor in combination therapy. Mavorixafor represents the first innovation in CN treatment in over 30 years and could become the first oral treatment available if approved.
X4 Pharmaceuticals (Nasdaq: XFOR), a biotechnology company focused on rare immune system diseases, has scheduled its first-quarter 2025 financial results announcement and corporate update for May 1, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT on the same day.
Investors and interested parties can access the conference call by dialing 1-800-343-4849 (US) or 1-203-518-9848 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.
X4 Pharmaceuticals (XFOR) has announced a 1-for-30 reverse stock split effective April 28, 2025. The split will reduce outstanding shares from approximately 173.6 million to 5.8 million, with trading on Nasdaq Capital Market beginning on the same date.
This strategic move comes after receiving a Nasdaq deficiency notice on August 13, 2024, due to the stock price falling below the required $1.00 minimum bid for 30 consecutive business days. While X4 received an additional compliance period until August 11, 2025, the reverse split aims to increase the stock price and maintain Nasdaq listing requirements.
The split will proportionally adjust equity incentive plans, stock options, and warrants. Stockholders with fractional shares will receive cash in lieu, and those with book-entry shares will see changes reflected in their accounts after April 28, 2025.
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards, effective January 31, 2025, consist of options to purchase 450,471 shares of X4's common stock at an exercise price of $0.2030 per share, matching the closing price on April 22, 2025.
The stock options, granted in accordance with Nasdaq Listing Rule 5635(c)(4), feature a ten-year term and a four-year vesting schedule. The vesting structure includes 25% of shares vesting after 12 months, followed by monthly vesting of the remaining shares over 36 months, contingent on continued employment.
X4 Pharmaceuticals (XFOR) reported its Q4 and full year 2024 financial results, highlighting significant progress in commercializing XOLREMDI® for WHIM syndrome and advancing clinical trials. Key financial metrics include $2.6 million in XOLREMDI® net revenues since its May 2024 launch, and $102.8 million in cash position as of December 31, 2024.
The company's Phase 3 4WARD trial for chronic neutropenia has reached ~90% site activation, with full enrollment expected in Q3/Q4 2025 and top-line data anticipated in 2H 2026. Notable achievements include the sale of a priority review voucher for $105 million and strategic partnerships in EU/ANZ and MENA regions, with Norgine Pharma providing a €28.5 million upfront payment.
Financial results show R&D expenses of $81.6 million and SG&A expenses of $61.5 million for 2024. The company implemented a strategic restructuring in February 2025, expected to reduce annual spending by $30-35 million. X4 projects sufficient funding into first half of 2026.
X4 Pharmaceuticals (XFOR), a company focused on rare immune system diseases, has scheduled its fourth-quarter and full-year 2024 financial results announcement for March 25, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day.
Investors and interested parties can access the conference call by dialing 1-800-267-6316 (US) or 1-203-518-9783 (International) using the conference ID: X4PHARMA. A live webcast will be available through X4's investor relations website, with a replay accessible after the call.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
